Canada: Court Of Appeal Upholds Decision Relating To Sildenafil; Antibody Patent Found Valid And Infringed (Intellectual Property Weekly Abstracts Bulletin: Week Of January 27, 2014)

Last Updated: January 30 2014
Article by Chantal Saunders, Beverley Moore, Adrian J. Howard and Ryan Steeves

Most Read Contributor in Canada, October 2017

Infringement Actions

Court of Appeal Upholds Decision Relating to Sildenafil Use Patent
Pfizer Ireland Pharmaceuticals v. Apotex Inc. , 2014 FCA 13
Drug: VIAGRA® sildenafil

In Apotex' action for impeachment of the Pfizer patent relating to the use of sildenafil to treat erectile dysfunction, Apotex brought a motion for summary judgment, which was granted by the Court. This is an appeal of that decision.

The Court of Appeal noted the litigation history of this patent, ending with a decision in a proceeding brought pursuant to the Patented Medicines (Notice of Compliance) Regulations (Regulations) by the Supreme Court of Canada (SCC) finding the patent invalid. This judgment was later amended by the SCC, resulting in the SCC dismissing the application for prohibition, instead of declaring the patent invalid.

In respect of Apotex' motion, brought and decided before the amendment by the SCC, the Court found that it was bound by the decision of the SCC finding the patent invalid because the disclosure is insufficient, even if the SCC ultimately amended the judgment. The Court of Appeal held that there was no error made by the Court in making this finding that warranted the intervention of the Court of Appeal.

Pfizer argued that the construction by the Court in the previous proceeding was not determinative for all purposes because the proceeding was brought pursuant to the Regulations. The Court of Appeal agreed but held that Pfizer should have provided evidence with respect to the construction.

The Court of Appeal considered the evidence that Pfizer adduced relating to testing that was done before the Canadian filing date and found "there is no disclosure that UK-114,542 was tested, and Pfizer has adduced no evidence that is capable of establishing that the skilled reader should have discerned from the specification that it was tested. Therefore, evidence that UK-114,542 was tested is not capable of established a genuine issue for trial on the question of the sufficiency of the disclosure."

Antibody Patent found Valid and Infringed
AbbVie Corporation v. Janssen Inc, 2014 FC 55
Drug: STELARA® ustekinumab

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie's patent relate to the use of a human antibody that binds to IL-12 with certain binding and potency properties. The patent was found to be valid and infringed.

The Court considered the admissibility of testing performed by AbbVie. The tests were conducted at two independent laboratories, however, Janssen was not present for the testing. After considering the reliability of the testing, the Court held that STELARA® fell within the binding and potency parameters of the claims.

A central issue relating to infringement centred around patent construction. The Court held that Janssen essentially conceded that if the claims covered human antibodies made by any method, then its STELARA® product fell within the scope of the claims, subject to the binding and potency parameters. The Court then held that the claims should be construed so as to cover human antibodies made by any method. The Court also held that Janssen promotes and sells STELARA® in Canada for the purpose of administering it to humans to treat psoriasis. Thus, Janssen induces infringement and is itself an infringer.

In considering validity, the Court held that the patent was not obvious. The Court then considered whether the claims were overly broad, as they claimed any antibody, however created, meeting certain parameters, and only described in detail one such antibody. The Court dismissed Janssens's policy argument that functional claiming should not be permitted, with the acknowledgement that it was AbbVie who confirmed that if an antibody did bind to IL-12, psoriasis could be treated. Furthermore, other minimum parameters were required. The Court also dismissed Janssen's fairness argument based on independent development, prolonged clinical studies and regulatory approval, when AbbVie does not have approval to sell a similar drug. The Court held that this should not prevent the one who first applies for, and gets, a patent, from having a good patent. Finally the Court considered whether the phrase "or less" made the claims ambiguous, and held that they were not.

The Court held that the claims of the patent that were at issue were valid as between the parties, but that the Patent Act does not provide for such a declaration in rem. The Court was disappointed with Counsel for not taking advantage of Case- and Trial-Management to narrow the issues and get the matter ready for trial. A number of specific inefficiencies were discussed. Thus, each party was ordered to bear their own costs. A second trial will be held to determine remedies and quantum.

Other Industry News

Health Canada has announced a Consultation on the Draft Guidance Document Quality (Chemistry and Manufacturing): New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs); and the Certified Product Information - Chemical Entities (CPID-CE) Guidance Document and Template. The consultation is open for comment until April 13, 2014.

Health Canada has announced a Consultation on a Revised Approach to NHP Site Licensing. The consultation is open for comment until April 23, 2014.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.